SFG
SRPT icon

SevenBridge Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

SevenBridge Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-400
Closed -$18K – 640
2017
Q3 		$18K Buy
+400
New +$16K 0.01% 387

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SevenBridge Financial Group's SRPT Position: Q4 2017 in Review

SevenBridge Financial Group sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 400 shares — an estimated $18K sold.

SevenBridge Financial Group first reported a position in SRPT in Q3 2017 and held it in 1 quarter. The position peaked at $18K in Q3 2017. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • SevenBridge Financial Group reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
  • SevenBridge Financial Group sold 400 Sarepta Therapeutics shares in Q4 2017, an estimated $18K.
  • SevenBridge Financial Group first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 1 quarter.
  • SevenBridge Financial Group's Sarepta Therapeutics position peaked at $18K in Q3 2017.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on SevenBridge Financial Group's 13F filing for Q4 2017, filed 20 Feb 2018.